VC firms in €30m series-D for Miracor

Belgian listed investment fund Quest for Growth (managed by Capricorn Venture Partners), took part in the financing alongside federal Belgian investment holding company SFPI and Meusinvest.

The fresh capital will be used to develop and commercialise the patented PiCSO Impulse System.

Previous funding
In June 2008, Earlybird and Delta co-led a €6m series-A for Miracor. The funding was earmarked for additional clinical trials and to gain CE marking for the company's PiCSO system.

SHS Gesellschaft für Beteiligungsmanagement led a series-B financing round for the company worth €7m in September 2011, and a series-B extension took place in 2015, with new investors BioMedPartners and AWS Gründerfonds investing €4.5m alongside existing backer Delta Partners.

New investor Peppermint Venture Partners committed to a €7m series-C round alongside existing investors in 2016.

Finally, the first tranche of the series-D round was closed at €25m in January 2018 with participation from all its previous investors as well as Meusinvest and Ming Capital.

Company
Founded in 2008, Miracor is a European medical device company dedicated to improving the clinical outcome of patients with impaired cardiac function. Its PiCSO system improves coronary myocardial perfusion by intermittently occluding the coronary sinus outflow resulting in improved perfusion of the infarcted area. The company was founded in Vienna, Austria, and has relocated to Awans, Belgium.

People
Ming Capital – Jack Bing Yang (managing partner).
Miracor Medical – Olivier Delporte (CEO).

• Tweet  
• Facebook  
• LinkedIn  
• Google plus  
• Send to  

• Topics
• Expansion
• Benelux
• DACH
• Healthcare
• Belgium
• Venture